Incretin mimetics like GLP-1 receptor (GLP-1R) agonists (for e.g., Liraglutide, Semaglutide), were initially developed for the treatment of Type 2 diabetes mellitus (T2DM) and obesity but have demonstrated therapeutic benefit across several domains in WS. This evidence concerns the gene GCG and Obesity.